The ADXS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ADXS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ADXS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ADXS Detailed Price Forecast - CNN Money||View ADXS Detailed Summary - Google Finance|
|View ADXS Detailed Summary - Yahoo! Finance||View ADXS Stock Research & Analysis - Zacks.com|
|View ADXS Trends & Analysis - Trade-Ideas||View ADXS Major Holders - Barrons|
|View ADXS Call Transcripts - NASDAQ||View ADXS Breaking News & Analysis - Seeking Alpha|
|View ADXS Annual Report - CompanySpotlight.com||View ADXS OTC Short Report - OTCShortReport.com|
|View ADXS Fundamentals - TradeKing||View ADXS SEC Filings - Bar Chart|
|View Historical Prices for ADXS - The WSJ||View Performance/Total Return for ADXS - Morningstar|
|View the Analyst Estimates for ADXS - MarketWatch||View the Earnings History for ADXS - CNBC|
|View the ADXS Earnings - StockMarketWatch||View ADXS Buy or Sell Recommendations - MacroAxis|
|View the ADXS Bullish Patterns - American Bulls||View ADXS Short Pain Metrics - ShortPainBot.com|
|View ADXS Stock Mentions - StockTwits||View ADXS Stock Mentions - PennyStockTweets|
|View ADXS Stock Mentions - Twitter||View ADXS Investment Forum News - Investor Hub|
|View ADXS Stock Mentions - Yahoo! Message Board||View ADXS Stock Mentions - Seeking Alpha|
|View Insider Transactions for ADXS - SECform4.com||View Insider Transactions for ADXS - Insider Cow|
|View ADXS Major Holdings Summary - CNBC||View Insider Disclosure for ADXS - OTC Markets|
|View Insider Transactions for ADXS - Yahoo! Finance||View Institutional Holdings for ADXS - NASDAQ|
|View ADXS Stock Insight & Charts - FinViz.com||View ADXS Investment Charts - StockCharts.com|
|View ADXS Stock Overview & Charts - BarChart||View ADXS User Generated Charts - Trading View|
Advaxis looks to raise $20 million via share offering
Posted on Thursday February 22, 2018
Developing new cancer therapies, alone, is a daunting mission. Couple that with a volatile stock market , and companies like Advaxis Inc. are at a big disadvantage. To secure enough capital to push innovative products through the pipeline, a stock offering may be needed.
Advaxis Prices $20.0 Million Public Offering of Common Stock
Posted on Thursday February 22, 2018
Advaxis, Inc. , a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies, announced today the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $2.00 per share.
Advaxis Announces Proposed Public Offering of Common Stock
Posted on Wednesday February 21, 2018
Advaxis, Inc. , a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union
Posted on Tuesday February 13, 2018
Advaxis, Inc. , a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies has submitted a conditional Marketing Authorization Application to the European Medicines Agency for the company’s lead Lm Technology product candidate, axalimogene filolisbac, for the treatment of adult women who progress beyond first-line therapy of persistent, ...